NO20062983L - Sulfonamid-derivater for behandling av sykdommer - Google Patents

Sulfonamid-derivater for behandling av sykdommer

Info

Publication number
NO20062983L
NO20062983L NO20062983A NO20062983A NO20062983L NO 20062983 L NO20062983 L NO 20062983L NO 20062983 A NO20062983 A NO 20062983A NO 20062983 A NO20062983 A NO 20062983A NO 20062983 L NO20062983 L NO 20062983L
Authority
NO
Norway
Prior art keywords
diseases
treatment
sulfonamide derivatives
compounds
disorders
Prior art date
Application number
NO20062983A
Other languages
English (en)
Norwegian (no)
Inventor
Kim James
Mark Edward Bunnage
David Anthony Price
Nicholas Murray Thomson
Alan Daniel Brown
Paul Alan Glossop
Charlotte Alice Louise Lane
Russell Andrew Lewthwaite
Ian Brian Moses
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062983(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20062983L publication Critical patent/NO20062983L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20062983A 2004-01-22 2006-06-27 Sulfonamid-derivater for behandling av sykdommer NO20062983L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
PCT/IB2005/000086 WO2005080313A2 (fr) 2004-01-22 2005-01-12 Derives de sulfonamides utilises dans le traitement de maladies

Publications (1)

Publication Number Publication Date
NO20062983L true NO20062983L (no) 2006-07-24

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062983A NO20062983L (no) 2004-01-22 2006-06-27 Sulfonamid-derivater for behandling av sykdommer

Country Status (30)

Country Link
US (4) US7244766B2 (fr)
EP (1) EP1708991B1 (fr)
JP (1) JP4020954B2 (fr)
AP (1) AP2359A (fr)
AR (1) AR047509A1 (fr)
AT (1) ATE375977T1 (fr)
AU (1) AU2005214153B2 (fr)
BR (1) BRPI0507085A (fr)
CA (1) CA2553789C (fr)
DE (1) DE602005002930T2 (fr)
DK (1) DK1708991T3 (fr)
DO (1) DOP2005000006A (fr)
EA (1) EA011167B1 (fr)
ES (1) ES2293530T3 (fr)
GE (1) GEP20094781B (fr)
MY (1) MY143390A (fr)
NL (1) NL1028087C2 (fr)
NO (1) NO20062983L (fr)
NZ (1) NZ548318A (fr)
OA (1) OA13362A (fr)
PA (1) PA8622001A1 (fr)
PE (1) PE20051136A1 (fr)
PL (1) PL1708991T3 (fr)
PT (1) PT1708991E (fr)
RS (1) RS50561B (fr)
SI (1) SI1708991T1 (fr)
TW (1) TWI341831B (fr)
UA (1) UA84048C2 (fr)
UY (1) UY28721A1 (fr)
WO (1) WO2005080313A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1708991B1 (fr) * 2004-01-22 2007-10-17 Pfizer Limited Dérivés des sulfonamides pour le traitement des maladies
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (fr) * 2005-02-24 2006-08-30 Neuro3D Sel d'Ocaperidone et composition pharmaceutique le contenant.
NZ585580A (en) * 2005-07-18 2011-08-26 Pfizer Ltd Process for the preparation of sulfonamide derivatives
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (fr) 2006-04-21 2013-09-18 Novartis AG Dérivés de purine comme agonistes des récepteurs de l'adénosine A2A
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
ES2442343T3 (es) 2008-12-30 2014-02-11 Pulmagen Therapeutics (Inflammation) Limited Compuestos de sulfonamida para el tratamiento de trastornos respiratorios
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
WO2013021309A1 (fr) 2011-08-11 2013-02-14 Pfizer Limited Intermédiaire et procédé de préparation d'un dérivé sulfonamide
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US229058A (en) * 1880-06-22 spencer
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) * 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
IL133575A0 (en) 1997-06-27 2001-04-30 Fujisawa Pharmaceutical Co Sulfonamide compounds, a method for producing same and pharmaceutical compositions containing same
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB2386906B (en) * 2002-03-26 2004-09-22 Japan Steel Works Ltd Heat-resisting steel and method of manufacturing the same
EP1507754A1 (fr) * 2002-05-28 2005-02-23 Theravance, Inc. Agonistes du recepteur adrenergique beta 2 alcoxy aryle
EP1477167A1 (fr) * 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
EP1708991B1 (fr) * 2004-01-22 2007-10-17 Pfizer Limited Dérivés des sulfonamides pour le traitement des maladies

Also Published As

Publication number Publication date
EP1708991A2 (fr) 2006-10-11
ES2293530T3 (es) 2008-03-16
US7528170B2 (en) 2009-05-05
GEP20094781B (en) 2009-09-25
UA84048C2 (ru) 2008-09-10
DOP2005000006A (es) 2005-07-31
US20100273758A1 (en) 2010-10-28
AP2359A (en) 2012-01-30
WO2005080313A9 (fr) 2006-08-31
RS50561B (sr) 2010-05-07
BRPI0507085A (pt) 2007-06-19
UY28721A1 (es) 2005-08-31
DE602005002930T2 (de) 2008-07-24
TW200530165A (en) 2005-09-16
JP4020954B2 (ja) 2007-12-12
PT1708991E (pt) 2007-12-14
CA2553789C (fr) 2011-07-19
EA200601223A1 (ru) 2006-12-29
JP2007518789A (ja) 2007-07-12
CA2553789A1 (fr) 2005-09-01
AU2005214153B2 (en) 2008-09-18
DK1708991T3 (da) 2008-01-14
AR047509A1 (es) 2006-01-25
EP1708991B1 (fr) 2007-10-17
US20080267970A1 (en) 2008-10-30
SI1708991T1 (sl) 2008-02-29
US7767715B2 (en) 2010-08-03
EA011167B1 (ru) 2009-02-27
PE20051136A1 (es) 2006-02-18
US20090197912A1 (en) 2009-08-06
NL1028087A1 (nl) 2005-07-25
PA8622001A1 (es) 2005-08-30
MY143390A (en) 2011-05-13
WO2005080313A2 (fr) 2005-09-01
AU2005214153A1 (en) 2005-09-01
US8013019B2 (en) 2011-09-06
WO2005080313A3 (fr) 2005-12-01
US20050182091A1 (en) 2005-08-18
NL1028087C2 (nl) 2006-05-09
OA13362A (en) 2007-04-13
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
ATE375977T1 (de) 2007-11-15
DE602005002930D1 (de) 2007-11-29
PL1708991T3 (pl) 2008-02-29
TWI341831B (en) 2011-05-11
AP2006003669A0 (en) 2006-06-30

Similar Documents

Publication Publication Date Title
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
NO20084005L (no) Aminderivater
NO20050828L (no) lndol-3-svovelderivater
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004080964A8 (fr) Derives d'indole utiles pour traiter des maladies
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
NO20055421L (no) Kinolinderivater som fosfodiestrase-inhibitorer
NO20074592L (no) Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister
AP2005003424A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them.
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE405576T1 (de) Androstan-17-alpha-carbonat zur verwendung bei der behandlung entzündlicher und allergischer zustände
NO20074258L (no) Pyridin-2-karboksamidderivater som MGLUR5 antagonister
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20082496L (no) Pyrazinderivater
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
NO20051503L (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20055854L (no) (2-hyroksy-2-(4-hydroksy-3-hydroksymetylfenyl)--etylamino)-propylfenylderivater som beta2 agonister
NO20065061L (no) Benzoksazin for behandling av sykdommer i luftveiene
EA200601462A1 (ru) Соединения для лечения заболеваний
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
ECSP055844A (es) Nuevos compuestos triciclicos
DE602006020295D1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application